Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cellsAdam J. Lamble, Nirali N. Shah, Toni Foley et al.|Blood Advances|2022Cited by 149
Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapyEmily M. Hsieh, Regina M. Myers, Bonnie Yates et al.|Blood Advances|2022Cited by 34
Cost comparison by treatment arm and center‐level variations in cost and inpatient days on the phase <scp>III</scp> high‐risk B acute lymphoblastic leukemia trial <scp>AALL</scp>0232Amanda M. DiNofia, Richard Aplenc, Alix E. Seif et al.|Cancer Medicine|2017Cited by 14
Characterization of Extramedullary Disease (EMD) Response to CD19 Targeted Chimeric Antigen Receptor T-Cells (CART) in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Multi-Site, Retrospective Cohort ReviewAlexander W. Rankin, Susan R. Rheingold, Regina M. Myers et al.|Transplantation and Cellular Therapy|2024Cited by 4
Clinical Factors Associated with Prolonged Cytopenias after CD19 Chimeric Antigen Receptor T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic LeukemiaRegina M. Myers, Michael A. Pulsipher, Yimei Li et al.|Blood|2024Cited by 2